Another active but not currently recruiting phase II/III study (NCT03548571)82 is evaluating the use of dendritic cell immunotherapy against cancer stem cells in newly diagnosed IDH-wt, MGMT-promoter methylated GBM patients receiving concomitant radiochemotherapy with temozolomide as first-line treatment. This evidence concerns the gene MGMT and glioblastoma.